4886 — ASKA Pharmaceutical Holdings Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareMicro Cap

Annual income statement for ASKA Pharmaceutical Holdings Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Tanshin	Yuho	Yuho	Yuho
Standards:	JAS	—	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	52,542	55,181	56,607	60,461	62,843
Cost of Revenue
Gross Profit	24,017	25,383	26,352	28,585	30,665
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	51,848	51,580	59,954	55,353	56,343
Operating Profit	694	3,601	-3,347	5,108	6,500
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	901	3,575	6,163	5,357	9,862
Provision for Income Taxes
Net Income After Taxes	649	2,714	4,290	4,239	7,546
Net Income Before Extraordinary Items
Net Income	649	2,714	4,290	4,239	7,546
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	649	2,713	4,290	4,238	7,545
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	43.6	95.9	121	152	267
Dividends per Share
Special Dividends per Share